Sanofi SA
PAR:SAN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
83.65
105.76
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SAN stock under the Base Case scenario is 109.7 EUR. Compared to the current market price of 94.4 EUR, Sanofi SA is Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sanofi SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SAN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Sanofi SA is a global healthcare leader, committed to improving health outcomes through the innovation and manufacturing of a diverse range of pharmaceutical products and vaccines. With its roots established over 150 years ago, the company operates a vast network that spans across 100 countries, employing over 100,000 individuals dedicated to advancing medical science. Sanofi's portfolio includes treatments in key therapeutic areas such as diabetes, cardiovascular diseases, and immunology, alongside its robust vaccine division, Sanofi Pasteur. This blend of established products and innovative pipelines, including biopharmaceuticals and gene therapies, positions Sanofi uniquely to meet the ev...
Sanofi SA is a global healthcare leader, committed to improving health outcomes through the innovation and manufacturing of a diverse range of pharmaceutical products and vaccines. With its roots established over 150 years ago, the company operates a vast network that spans across 100 countries, employing over 100,000 individuals dedicated to advancing medical science. Sanofi's portfolio includes treatments in key therapeutic areas such as diabetes, cardiovascular diseases, and immunology, alongside its robust vaccine division, Sanofi Pasteur. This blend of established products and innovative pipelines, including biopharmaceuticals and gene therapies, positions Sanofi uniquely to meet the evolving healthcare demands of a global population.
For investors, Sanofi represents a compelling opportunity due to its strong commitment to research and development, which accounted for approximately 16% of its revenue last year. The company’s strategic initiatives focus on enhancing its product line while also forming strategic alliances and partnerships to foster innovation. Furthermore, Sanofi’s solid financial performance, characterized by consistent revenue growth and healthy dividend payouts, showcases its operational efficiency and reliability. As the healthcare landscape continues to shift, Sanofi's agility in adapting to new challenges, coupled with its focus on science and patient needs, sets it apart as a strong contender in the biopharmaceutical industry, providing investors with a platform for sustainable long-term growth.
Sanofi SA is a global healthcare company based in France that operates in various segments of the pharmaceutical and healthcare industries. The core business segments of Sanofi include:
-
Pharmaceuticals: This segment focuses on prescription medications and includes several therapeutic areas, notably:
- Diabetes and Cardiovascular: Sanofi offers a range of medications for diabetes management, including insulin and related products, as well as treatments for cardiovascular diseases.
- Specialty Care: This includes treatments for conditions such as rare diseases, immunology, and oncology. Sanofi has developed therapies for conditions like multiple sclerosis, hemophilia, and certain cancers.
- Consumer Healthcare: Over-the-counter products that contribute to maintaining health and wellness, including pain relief, allergy medications, and other everyday healthcare items.
-
Vaccines (Sanofi Pasteur): Sanofi’s vaccines division is one of the largest in the world, providing a wide range of vaccines for infectious diseases. This segment develops, manufactures, and markets vaccines against diseases such as influenza, meningitis, and polio.
-
Consumer Healthcare: This segment encompasses a variety of over-the-counter health products that help improve consumer wellness. Sanofi produces well-known brands in categories such as pain relief, digestive health, and vitamins.
-
Research and Development: Sanofi invests significantly in R&D to discover and develop new medicines and vaccines. This includes a focus on innovation in biologics and gene therapy, alongside traditional pharmaceutical developments.
-
Emerging Markets: Sanofi has been expanding its presence in emerging markets, providing access to medicines and health solutions in regions with growing healthcare needs.
Each of these segments represents an essential aspect of Sanofi’s overall business strategy, focusing on delivering innovative healthcare solutions while maintaining a commitment to improving patient access and outcomes globally.
Sanofi SA, a global biopharmaceutical company, possesses several unique competitive advantages that distinguish it from its rivals in the pharmaceutical industry:
-
Diverse Product Portfolio: Sanofi has a well-balanced portfolio across various therapeutic areas, including diabetes, oncology, vaccines, and rare diseases. This diversification helps mitigate risks associated with reliance on a single product or therapeutic area and can provide stable revenue streams.
-
Strong Research and Development (R&D): Sanofi invests significantly in R&D, allowing it to innovate and develop new therapies. Its focus on biologics and specialty pharmaceuticals enables it to create complex drugs that can command premium pricing and exhibit less competition compared to traditional pharmaceuticals.
-
Established Vaccine Division: Sanofi Pasteur is one of the largest vaccine manufacturers globally, giving the company a strong foothold in an essential healthcare sector. This division can generate consistent revenue, especially during health crises, such as the COVID-19 pandemic.
-
Global Presence and Scale: With operations in more than 100 countries, Sanofi benefits from economies of scale and global reach, allowing it to leverage its manufacturing capabilities and distribution networks effectively.
-
Strategic Partnerships and Collaborations: Sanofi has formed numerous strategic alliances with biotech firms, academic institutions, and other pharmaceutical companies, facilitating the sharing of resources, technology, and expertise.
-
Regulatory Expertise: Sanofi has extensive experience navigating complex regulatory environments across different regions, allowing it to bring products to market more efficiently and effectively than some competitors.
-
Strong Brand Recognition: Over the years, Sanofi has built a reputation for quality and reliability within the healthcare sector, enhancing customer loyalty and trust that can lead to sustained revenue.
-
Focus on Patient Solutions: Sanofi demonstrates a commitment to providing integrated healthcare solutions beyond pharmaceuticals, such as patient support programs and digital health initiatives, thus creating added value for patients and healthcare providers.
-
Sustainability Initiatives: With a growing emphasis on sustainability in the healthcare industry, Sanofi’s initiatives aimed at reducing its environmental impact could enhance its brand reputation and appeal among socially conscious investors and clients.
These advantages allow Sanofi to maintain a competitive edge, enabling it to adapt to the evolving pharmaceutical landscape, respond to market demands effectively, and continue its growth trajectory.
Sanofi SA, like many pharmaceutical companies, faces a variety of risks and challenges in the near future. These risks can be categorized into several broad areas:
-
Regulatory Risks:
- Approval and Compliance: The pharmaceutical industry is heavily regulated. Delays, rejections, or changes in regulatory requirements for drug approvals can significantly impact Sanofi's product pipeline and market access.
- Pricing Regulations: Increasing governmental scrutiny and regulations around drug pricing in various markets can affect profitability.
-
Competitive Landscape:
- Generic Competition: As patents on key products expire, generic versions may enter the market, leading to a decrease in revenue.
- Innovation from Competitors: The rapid pace of innovation in biotech and pharmaceuticals means that Sanofi must continuously invest in R&D to keep up with competitors.
-
Market Dynamics:
- Changes in Healthcare Policies: Shifts in healthcare policies, especially in major markets such as the U.S. and Europe, can impact drug access and reimbursement, affecting sales.
- Economic Slowdown: Global economic challenges can lead to reduced healthcare spending, affecting demand for Sanofi’s products.
-
Supply Chain Vulnerabilities:
- Disruption Risks: Events such as natural disasters, geopolitical tensions, or pandemics can disrupt the supply chain, impacting the availability of raw materials and finished products.
- Quality Control: Ensuring consistent quality in manufacturing is critical, and any failures can lead to recalls and reputational damage.
-
Technological Changes:
- Digital Health Trends: The rise of telemedicine and digital therapeutics could change how patients access treatments, potentially affecting Sanofi's sales.
- Data Security: As reliance on digital health platforms grows, so does the risk of data breaches and cyber-attacks.
-
Reputation Risks:
- Public Perception: Negative press related to drug pricing, safety concerns, or ethical issues in clinical trials could damage the company's reputation and affect stock prices.
-
Pipeline Risk:
- Reliance on Upcoming Products: The success of Sanofi heavily depends on its ability to successfully bring new products to market. Failure to achieve expected outcomes in clinical trials can have significant implications.
-
Global Health Challenges:
- Pandemic Preparedness: Ongoing public health challenges like COVID-19 may require strategic shifts and innovations in response to emerging health crises.
Addressing these challenges will require Sanofi to not only be agile and adaptable but also to maintain a strong focus on innovation and strategic partnerships. Continued investment in R&D, effective risk management strategies, and maintaining a positive corporate reputation will be critical for navigating the landscape ahead.
Revenue & Expenses Breakdown
Sanofi SA
Balance Sheet Decomposition
Sanofi SA
Current Assets | 30.1B |
Cash & Short-Term Investments | 6.8B |
Receivables | 8.8B |
Other Current Assets | 14.5B |
Non-Current Assets | 99.7B |
Long-Term Investments | 2.6B |
PP&E | 11.9B |
Intangibles | 76.7B |
Other Non-Current Assets | 8.4B |
Current Liabilities | 30B |
Accounts Payable | 7.4B |
Short-Term Debt | 215m |
Other Current Liabilities | 22.4B |
Non-Current Liabilities | 27B |
Long-Term Debt | 14.2B |
Other Non-Current Liabilities | 12.8B |
Earnings Waterfall
Sanofi SA
Revenue
|
61.6B
EUR
|
Cost of Revenue
|
-18.8B
EUR
|
Gross Profit
|
42.7B
EUR
|
Operating Expenses
|
-28.7B
EUR
|
Operating Income
|
14B
EUR
|
Other Expenses
|
-7B
EUR
|
Net Income
|
7B
EUR
|
Free Cash Flow Analysis
Sanofi SA
EUR | |
Free Cash Flow | EUR |
In Q3 2024, Sanofi achieved a remarkable €13.4 billion in sales, marking a 16% increase year-over-year at constant exchange rates. The strong performance was driven by Dupixent, which reported nearly €3.5 billion in sales, and a robust 26% growth in its vaccines segment. The company raised its 2024 EPS guidance, projecting at least a low single-digit percentage growth, previously expected to be flat. Beyfortus sales are projected to reach around €1.5 billion in 2024, while ongoing investments in R&D are expected to increase by €700 million this year, demonstrating a commitment to innovation and growth.
What is Earnings Call?
SAN Profitability Score
Profitability Due Diligence
Sanofi SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Sanofi SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
SAN Solvency Score
Solvency Due Diligence
Sanofi SA's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Sanofi SA's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SAN Price Targets Summary
Sanofi SA
According to Wall Street analysts, the average 1-year price target for SAN is 114.94 EUR with a low forecast of 90.9 EUR and a high forecast of 136.5 EUR.
Dividends
Current shareholder yield for SAN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SAN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 95,442 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one SAN stock under the Base Case scenario is 109.7 EUR.
Compared to the current market price of 94.4 EUR, Sanofi SA is Undervalued by 14%.